Objective-Pyripyropene A (PPPA) of fungal origin is the first compound that has been found to strongly and selectively inhibit acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) isozyme activity in vitro. The purpose of the present study was to investigate in vivo efficacy of the ACAT2-selective inhibitor in atherosclerosis. Methods and Results-PPPA treatment (10 to 100 mg/kg) caused 30.5Ϯ4.7% to 55.8Ϯ3.3% inhibition of the cholesterol absorption from the mouse intestine. When PPPA (10 to 50 mg/kg per day) was orally administered to apolipoprotein E-knockout mice for 12 weeks, the levels of plasma cholesterol, very-low-density lipoprotein (VLDL), and low-density lipoprotein (LDL) and hepatic cholesterol content were lowered. Furthermore, the ratio of cholesteryl oleate (exclusively synthesized in hepatic ACAT2) to cholesteryl linoleate in VLDL-and LDL-derived cholesteryl ester decreased, indicating that hepatic ACAT2 activity was inhibited by PPPA. PPPA-treated mice had reduced atherogenic lesion areas that were lowered by 26.2Ϯ3.7% to 46Ϯ3.8% in the aortae and by 18.9Ϯ3.6% to 37.6Ϯ6.0% in the hearts. Conclusion-Our findings indicate that ACAT2-selective inhibition in the intestine and the liver can be effective against atherosclerosis and that PPPA appears to be a potential antiatherogenic lead compound. This study is the first demonstration of the in vivo efficacy of PPPA, an ACAT2-selective inhibitor, in atherosclerosis. PPPA-treated atherogenic mice showed a decrease in intestinal cholesterol absorption and cholesterol and cholesteryl oleate levels in both LDL and VLDL, resulting in protection of atherosclerosis development. (Arterioscler Thromb Vasc Biol. 2011; 31:1108-1115.)
C ardiovascular diseases are a group of disorders of the heart and blood vessels. They represent the leading cause of death globally, with more individuals dying each year from cardiovascular diseases than from any other cause. Statins, which are inhibitors of 3-hydroxy-3-methylglutarylcoenzyme A reductase, reduce the risk of complications and death from cardiovascular events by approximately 30%. 1 Consequently, the quest for novel pharmacological agents that target specific steps of atherogenesis has intensified significantly in recent years. The enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT), which catalyzes the synthesis of cholesteryl ester (CE) from free cholesterol and long-chain fatty acyl-coenzyme A, has been considered a promising therapeutic target. 2 Although a number of synthetic ACAT inhibitors have been developed, they have failed to reduce cardiovascular events in clinical trials.
Two ACAT isozymes have been identified in mammals: ACAT1 and ACAT2. [3] [4] [5] [6] Each isozyme has a distinct pattern of expression among tissues. Although ACAT1 is ubiquitously expressed at a high level in sebaceous glands, steroidogenic tissues, and macrophages, ACAT2 is expressed predominantly in the liver and intestine. 7 ACAT1-selective inhibition may cause detrimental effects, 8 -10 whereas ACAT2-selective inhibition has consistently shown antiatherosclerotic activity. 11, 12 However, recently developed compounds, such as avasimibe 13 and pactimibe, 14, 15 which can inhibit both ACAT1 and ACAT2 nonselectively, reportedly fail to inhibit the progression coronary and carotid atherosclerosis. These findings led to declining interest in the development of ACAT inhibitors, including ACAT2-selective ones. 16 One of the reasons for the negative results may be that inhibition of ACAT1 activity in vascular cells, including macrophages, is cytotoxic because of the excessive accumulation of free cholesterol in these cells. 8, 10, 17 These changes may stimulate the development of atherosclerosis by aggravating vascular inflammation. More importantly, we would assume that these compounds did not effectively inhibit ACAT activities in humans in vivo based on the manner of their administration. If they had effectively inhibited ACAT2 activity either in the liver or intestine, they would have significantly decreased plasma cholesterol levels. In mice, effective inhibition of ACAT2 has been shown to substantially reduce plasma cholesterol levels, even though the inhibition is restricted to the liver. 11, 12, 18 These considerations prompted us to develop ACAT2-selective inhibitors that effectively and safely inhibit ACAT2 activities in the liver and/or intestine.
Since 1990, our research group has been screening for ACAT inhibitors of natural origin, which possess chemical structures different from those seen in synthetic compounds. As a result, we have found several ACAT inhibitors. 19 Among them, the pyripyropenes, isolated from the culture broth of Aspergillus fumigatus FO-1289, were found to be one of the most potent ACAT inhibitors in an enzyme assay using rat liver microsomes. 20 -22 To investigate the selectivity of ACAT inhibitors toward each of the 2 isozymes, ACAT1 and ACAT2, we used 2 cell lines (designated ACAT1-CHO and ACAT2-CHO), in which ACAT1 and ACAT2 genes from the African green monkey (Chlorocebus aethiops) were transfected into the ACAT-deficient Chinese hamster ovary cell line AC29. 23 Several ACAT inhibitors were evaluated in a cell-based assay, and the IC 50 values of our compounds 24 and typical synthetic inhibitors previously reported 25, 26 are summarized in the Table. Most ACAT inhibitors were nonselective, inhibiting both ACAT1 and ACAT2 with similar potency (Ϫ1Ϲselectivity indexϹϩ1). Avasimibe and pactimibe belong in this class. 25, 26 Synthetic Wu-V-23, K-604, and fungal beauveriolides I and III appeared to be ACAT1-selective inhibitors (selectivity in-dexϽϪ1). 23, 24, 26 Only fungal pyripyropenes showed a selective ACAT2-inhibiting property, the nature of which has now been defined. 27 Notably, no ACAT2-selective small molecule inhibitors other than pyripyropene have been reported to date. 23, 24, 28 Accordingly, all natural and semisynthetic pyripyropenes prepared were reevaluated in cell-based assays, 29 and pyripyropene A (PPPA) ( Figure 1A ) was found to be a highly selective and potent ACAT2 inhibitor (IC 50 70 nmol/L; selectivity indexϾϩ3.06).
Attempts to clinically use the dual inhibitors avasimibe 13 and pactimibe 14, 15 were unsuccessful. Nissen et al reported that ACAT inhibition by pactimibe did not appear to slow the progression of atherosclerosis, and they suggested that it may even have promoted atherogenesis, probably because inhibition of ACAT1 activity by the drug in macrophages may increase free cholesterol levels without enhancing efflux of free cholesterol, thereby inducing cytotoxicity. 14 These authors presented a pessimistic view of ACAT inhibitors, including ACAT2-selective inhibitors, although the objective basis for such a conclusion was not made clear. 16 Unsurprisingly, many investigators subsequently lost interest in further development of ACAT inhibitors. Nevertheless, Bell et al demonstrated that liver-selective knockdown of ACAT2, using an antisense oligonucleotide approach, reduced hepatic and plasma cholesterol concentrations, thus promoting atheroprotection in mice. 18 ACAT2-selective inhibitors are needed to determine whether the strategy of ACAT inhibition reduces atherosclerosis. 30 -32 With the availability of the ACAT2 selective inhibitor PPPA, we were stimulated to investigate whether or not PPPA shows in vivo antiatherosclerotic activity. To our knowledge, this is the first study investigating the in vivo efficacy of any ACAT2-selective inhibitor in a mouse model of atherosclerosis.
Methods
Detailed descriptions of experimental methods are available in the supplemental materials, available online at http://atvb.ahajournals.org.
Materials
PPPA was purified from a culture broth of the producing fungus, A. fumigatus FO-1289, according to established methods. 20 -22 
Mice and Diet
Male C57BL/6 mice were obtained from Crea Japan. Male apolipoprotein E knockout (Apoe Ϫ/Ϫ ) mice and low-density lipoprotein receptor knockout (Ldlr Ϫ/Ϫ ) mice were purchased from the Jackson Laboratory. Two diets were used: regular chow (CE-2, Crea Japan) and a Western-type diet containing 21% fat and 0.2% cholesterol by weight (D12079B, Research Diet).
Statistical Analyses
Experimental data are expressed as meanϮSEM, and statistically significant differences among treatments were detected by 1-way ANOVA (PϽ0.05) using GraphPad Prism software, unless otherwise stated. When ANOVA results were statistically significant, individual treatment comparisons were made using the Tukey post test analysis.
Results
First, we evaluated the effect of PPPA on the proposed role of ACAT2 in cholesterol absorption from the intestines in C57BL/6 mice fed a Western-type diet, using a fecal dual isotope method. 11, 33 Male mice were assigned to 5 treatment groups (PPPA at 0, 1, 10, 50, and 100 mg/kg body weight). 23 Terasaka, 25 and Ikenoya et al. 26 Figure 1B , PPPA treatment significantly decreased cholesterol absorption in a dosedependent fashion in C57BL/6 mice (30.5Ϯ4.7, 48.9Ϯ2.2%, and 55.8Ϯ3.3% inhibition of cholesterol absorption at doses of 10, 50, and 100 mg/kg, respectively). To determine whether PPPA induces the expression of ACAT2 in the intestine, we measured ACAT activity and mRNA levels (ACAT2 expression) in the intestine (segments I-2 and I-3). As shown in Figure 1C , PPPA treatment had no effect, indicating that ACAT2 inhibition in the intestine by PPPA was reversible. As shown in Figure 1D and Supplemental Figure I , PPPA had no effect on mRNA levels (for example, LDL receptor and HMG-CoA reductase) involved in cholesterol metabolism (target genes and primer pairs used are described in Supplemental Table I Figure II) . To investigate whether PPPA-mediated ACAT2 inhibition would be beneficial for atherosclerosis, Apoe Ϫ/Ϫ mice received daily oral PPPA treatment (0, 10, 25, and 50 mg/kg per day) for 12 weeks while being fed a Western-type diet. No significant changes were observed on body weight, plasma glucose, plasma alanine transferase, plasma blood urea nitrogen, and food intake in PPPA-treated mice (Figure 2 and Supplemental Figure III) , indicating that PPPA treatment did not exert toxic effects on liver and kidney and had no effect on glucose metabolism. Total plasma cholesterol levels during PPPA treatment are shown in Figure 3A . PPPA treatment at 25 and 50 mg/kg per day after 12 weeks significantly lowered the total plasma cholesterol levels by 23.0Ϯ4.9% and 30.9Ϯ4.3%, respectively. Interestingly, the cholesterollowering effect was evident as early as 2 weeks after start of treatment. Furthermore, lipoprotein analyses revealed that the reduction of cholesterol levels in the plasma after the 12week treatment was mainly attributed to lower cholesterol levels in the atherogenic low-density lipoprotein (LDL) and VLDL fractions ( Figure 3B and 3C ). Cholesterol levels in chylomicron and high-density lipoprotein fractions appeared unaffected by PPPA treatment (Figure 3B and 3C ). As shown in Supplemental Figure IV , plasma triglyceride levels appeared to be elevated primarily at the highest dose of PPPA (50 mg/kg per day).
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To further investigate differences in hypercholesterolemia, the fatty acid composition of VLDL-and LDL-CE in the plasma of PPPA-treated mice after 12 weeks was examined ( Figure 3D ). PPPA treatment resulted in a lower cholesteryl oleate percentage and a higher cholesteryl linoleate percentage, with this change appearing to occur mostly in a dosedependent fashion ( Supplemental Table II ). In addition, both hepatic CE and cholesteryl oleate levels were reduced in PPPA-treated mice in a dose-dependent fashion ( Figure 4A and 4B). However, ACAT activity and mRNA levels (ACAT1 and ACAT2) in the liver (including hepatocytes and Kupffer cells) were almost the same as those of control group ( Figure 4C and 4D) , indicating that PPPA treatment had no effect on ACAT activity as measured in vitro, nor on the abundance of ACAT1 and ACAT2 mRNA in the liver. Furthermore, no significant differences in gene expression were observed to account for the shift in the hepatic cholesterol metabolism (target genes and primer pairs used are described Supplemental Table I) Figure 5A ). Furthermore, the cross-sections of the aortic sinuses of the hearts showed a marked thickening of the intima in control mice ( Figure 5C, control) . The atherosclerotic lesion areas in the PPPA-treated groups were significantly reduced (5.97Ϯ 0.4ϫ10 5 Figure 5D ). Thus, the ACAT2selective inhibitor PPPA was demonstrated in vivo to show atheroprotective activity. It is well known that there are good correlations between the morphometric assessment and the content of CE and free cholesterol in the lesion areas. 34 Therefore, the aortic CE and free cholesterol contents were measured to quantify the extent of atherosclerosis within the aortae ( Figure 5E) , confirming the in vivo atheroprotective activity of PPPA. Moreover, we evaluated macrophage distribution in aortic lesions of the hearts by immunohistochemistry using the macrophage marker MOMA-2. However, PPPA treat-ment had no effect on macrophage contents and distribution ( Figure 5F and Supplemental Figure VI) . Similarly, antiatherosclerotic activity of PPPA (10, 25, and 50 mg/kg per day, oral administration for 12 weeks) was tested in Ldlr Ϫ/Ϫ mice. The atherosclerotic lesion areas in the aortae and hearts of the PPPA-treated mice were significantly reduced, showing atheroprotective activity of PPPA in Ldlr Ϫ/Ϫ mice (Supplemental Figure VII) .
Discussion
Although a number of ACAT inhibitors have been reported so far, the selectivity of such ACAT inhibitors toward the 2 ACAT isozymes has not been extensively investigated. Stimulated by the experiments by Bell et al 18 using antisense oligonucleotide to ACAT2, the finding of the unique property of PPPA, inhibition of ACAT2, prompted us to investigate whether in vivo antiatherosclerotic activity could be found.
We evaluated the effect of PPPA on the proposed role of ACAT2 in the mouse intestine (cholesterol absorption) by the conventional methods. 11, 33 First, treatment with PPPA significantly inhibited cholesterol absorption from the intestine by the fecal dual isotope method ( Figure 1B) , confirming the ACAT2 function in the intestine. Furthermore, detailed analyses of the fatty acid composition of VLDL-and LDLderived CE in the plasma and the cholesterol and CE levels in the liver of PPPA-treated mice after 12 weeks strongly suggested that PPPA inhibited ACAT2 function in the liver. The ratio of cholesteryl oleate (mainly produced by hepatic ACAT2) to cholesteryl linoleate (produced by lecithin-cholesterol acyltransferase (LCAT) in the plasma) in VLDL-and LDL-derived CE decreased ( Figure 3D and Supplemental  Table II ), indicating that hepatic ACAT2 activity in the liver was inhibited by PPPA. The shift in the lipoprotein profile in the plasma of PPPA-treated mice also was analogous to that found in ACAT2-deficient and ACAT2 antisense oligonucleotide-treated mice. 11, 12, 18 Evidence is accumulating that 
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plasma cholesteryl oleate is produced by hepatic ACAT2, in addition to our previous reports. [35] [36] [37] Genetic deletion of ACAT2 in mice altered LDL CE fatty acid composition with a shift from oleate to linoleate. 35 Moreover, Warensjo et al have suggested that higher proportions of plasma cholesteryl oleate and cholesteryl palmitate, which are produced by hepatic ACAT2, are associated with an increased risk of cardiovascular-related death. 38 The PPPA-related dosedependent reduction in hepatic CE was associated with decreased cholesteryl oleate levels ( Figure 4B ) that in turn lead to a lower level of atherogenic plasma lipoproteins secreted by the liver. ACAT2-deficient mice were reported to have lower ACAT activity in the intestine and the liver. 11 Moreover, liverselective ACAT2 antisense oligonucleotide-treated mice were reported to have lower ACAT2 activity in the liver. 18 However, ACAT activity in microsomes prepared from the intestine and liver of PPPA-treated mice showed almost the same levels as control mice (Figures 1 and 4) . In fact, we found that the mRNA levels of ACAT2 in the intestine and liver of PPPA-treated mice were almost the same as those of control mice and that ACAT2 activity was recovered by dilution or dialysis of PPPA-treated enzyme or microsomes. These data indicated that PPPA treatment had no effect on gene expression or mRNA levels of ACAT2 in mice and that ACAT inhibition by PPPA is reversible. Furthermore, we demonstrated that PPPA is noncovalently bound to a specific site (Gln492-Val493-Ser494) of the ACAT2 isozyme. 27 The atherosclerotic lesion areas and CE content in the aortae and hearts of mice treated for 12 weeks with PPPA significantly decreased. However, PPPA treatment had no effect on macrophage content and function in aortae ( Figure  5 and Supplemental Figure VI) . Thus, we concluded that PPPA selectively inhibits the function of ACAT2 activity in the intestine and liver to reduce the plasma cholesterol (cholesteryl oleate) levels, leading to the atheroprotective effects seen in these atherogenic mouse models.
During the experiments, no toxic effects on the liver and kidney caused by PPPA treatment were observed in mice, although body weight was slightly reduced (Figure 2 ). Most ACAT inhibitors so far developed have had problems with side effects, such as diarrhea and toxicity to certain tissues. 39, 40 Additionally, all the previously developed drugs except PPPA also inhibited ACAT1 activity, which may increase free cholesterol levels in macrophages and, with limited efflux of free cholesterol, potentially induce cytotoxicity, 8, 10, 17 although such severe effects were not prominent in all mouse experiments. PPPA showed no effect on macrophages in aortae and ACAT1 activity in macrophages, 24 leading us to expect that PPPA would show no toxic effect on macrophages in human beings. We previously reported the antiatherosclerotic activity of other fungal metabolites beauveriolides I and III under the same experimental conditions. 41 The target enzyme of beauveriolides is believed to be ACAT1; the drugs appeared to be nonselective in enzyme assays using microsomes, although they selectively inhibited ACAT1 activity in cell-based assays, 24 in which case the specific beauveriolide effects in vivo remain unclear. During treatment with beauveriolides in Apoe Ϫ/Ϫ mice and Ldlr Ϫ/Ϫ mice, the plasma cholesterol levels were within the same range as the plasma cholesterol levels of untreated mice, although atheroprotective activity was demonstrated after 8 weeks of treatment. 41 Accordingly, sufficient plasma cholesterol-lowering activity might have been caused by some degree of ACAT2 inhibition. Measurement of cholesteryl oleate was not attempted in those studies.
Our findings suggest that ACAT2-selective inhibition by PPPA can protect against the development of atherosclerosis in both Apoe Ϫ/Ϫ mice and Ldlr Ϫ/Ϫ mice. Atheroprotection was associated with decreased intestinal cholesterol absorption and lower cholesterol concentration and cholesteryl oleate content in both LDL and VLDL. In conclusion, these data suggest that ACAT2 should still be considered as a potential target for the treatment of atherosclerosis, and PPPA, as the only reported ACAT2-selective inhibitor, appears to be a good potential lead candidate for the development of novel antiatherogenic compounds.
